A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor.

Antibodies, Bispecific Breast Neoplasms / drug therapy Cancer-Associated Fibroblasts Cell Line, Tumor Doxorubicin Female Humans Liposomes Nanomedicine Polyethylene Glycols

Journal

Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571

Informations de publication

Date de publication:
21 Dec 2021
Historique:
pubmed: 27 11 2021
medline: 24 12 2021
entrez: 26 11 2021
Statut: epublish

Résumé

The therapeutic efficacy of methoxypolyethylene glycol (mPEG)-coated nanomedicines in solid tumor treatment is hindered by tumor-associated fibroblasts (TAFs), which promote tumor progression and form physical barriers. We developed an anti-HER2/anti-FAP/anti-mPEG tri-specific antibody (TsAb) for one-step conversion of mPEG-coated liposomal doxorubicin (Lipo-Dox) to immunoliposomes, which simultaneously target HER2

Identifiants

DOI: 10.1039/d1bm01218e PMID: 34826322
pubmed: 34826322
doi: 10.1039/d1bm01218e
doi:

Substances chimiques

Antibodies, Bispecific 0
Liposomes 0
Polyethylene Glycols 3WJQ0SDW1A
Doxorubicin 80168379AG
monomethoxypolyethylene glycol 9004-74-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

202-215

Auteurs

Michael Chen (M)

Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
ORCID: 0000-0001-8899-9661

Ming-Thau Sheu (MT)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

Tian-Lu Cheng (TL)

Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung City, Taiwan.
ORCID: 0000-0003-0004-8840

Steve R Roffler (SR)

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Shyr-Yi Lin (SY)

Department of Primary Care Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Department of General Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.

Yi-Jou Chen (YJ)

Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.

Yi-An Cheng (YA)

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung City, Taiwan.
ORCID: 0000-0002-3204-2526

Jing-Jy Cheng (JJ)

Department of General Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan.

Hsin-Yu Chang (HY)

Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.

Tung-Yun Wu (TY)

Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
ORCID: 0000-0002-7844-3157

An-Pei Kao (AP)

Stemforce Biotechnology Co., Ltd, Chiayi City, Taiwan.

Yuan-Soon Ho (YS)

TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. hoyuansn@tmu.edu.tw.
Cancer Research Center, Taipei Medical University Hospital, Taipei, Taiwan.

Kuo-Hsiang Chuang (KH)

Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
Traditional Herbal Medicine Research Center of Taipei Medical University Hospital, Taipei, Taiwan. khchuang@tmu.edu.tw.
Ph.D Program in Biotechnology Research and Development, Taipei Medical University, Taipei, Taiwan.
Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, Taipei Medical University, Taipei, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Cellules › Cellules du tissu conjonctif › Fibroblastes › Fibroblastes associés au cancer › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Doxorubicine › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomimétiques › Membrane artificielle › Liposomes › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Miniaturisation › Nanotechnologie › Nanomédecine › A novel anti-tumor/anti-tumor-associated...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › A novel anti-tumor/anti-tumor-associated...